Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Provides Support for U.S. Disaster-Relief Efforts
More than 6 Million Doses of Medicine Plus Financial and Other Assistance Provided to Affected Areas
View HTML
Toggle Summary Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
Mylan Also Receives U.S. FDA Approval of Generic for Copaxone® 20 mg/mL Once-Daily
View HTML
Toggle Summary Mylan Launches Generic Cancidas® for Injection
HERTFORDSHIRE, England and PITTSBURGH , Oct. 2, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic versions of Merck's Cancidas®. Mylan received final approval from the U.S.
View HTML
Toggle Summary Mylan Launches Generic Gleevec® Tablets
HERTFORDSHIRE, England and PITTSBURGH , Sept. 29, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Imatinib Mesylate Tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec® Tablets. Mylan received final approval from the U.S.
View HTML
Toggle Summary Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets
HERTFORDSHIRE, England and PITTSBURGH , Sept. 14, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy
View HTML
Toggle Summary Mylan Names Dennis Zeleny as Chief Human Relations Officer
HERTFORDSHIRE, England and PITTSBURGH , Sept. 13, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Dennis Zeleny as chief human relations officer. Zeleny joins Mylan with 30 years of experience leading global, corporate HR organizations and consulting on HR
View HTML
Toggle Summary Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries
TOKYO , HERTFORDSHIRE, England and PITTSBURGH , Aug. 24, 2017 /PRNewswire/ -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private
View HTML
Toggle Summary Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen® Auto-Injector
HERTFORDSHIRE, England and PITTSBURGH , Aug. 17, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that its subsidiaries, Mylan Inc. and Mylan Specialty L.P. , have signed an agreement with the U.S. Department of Justice ("DOJ") and two relators finalizing the Medicaid drug
View HTML
Toggle Summary Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada ® , Atripla ® and Viread ® to patients in Canada 1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO , Aug. 10, 2017 /PRNewswire/ -- Mylan Pharmaceuticals ULC , a subsidiary of Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company,
View HTML
Toggle Summary Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance
HERTFORDSHIRE , England and PITTSBURGH , Aug. 9, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and six months ended June 30, 2017 . Second Quarter 2017 Financial Highlights Total revenues of $2.96 billion , up 16% compared to the prior
View HTML